Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Steven Fliesler, PhD

Development and characterization of mouse models of RP59 DHDDS deficiency. Steven Fliesler (Co-Principal Investigator). National Eye Institute/NIH. $2,208,923. 9/1/2018-6/1/2022.
Clinical Translational Science Award (CTSA). Steven Fliesler (Co-Investigator), John Canty, Jr. (Co-Principal Investigator), Margarita Dubocovich (Principal Investigator), Peter Elkin (Co-Investigator), Leonard Epstein (Co-Investigator), Alan Hutson (Co-Investigator), Gene Morse (Co-Investigator), Sanjay Sethi (Co-Investigator), Laurene Tumiel Berhalter (Co-Investigator). National Institutes of Health. $16,000,000. 1/1/2016-1/1/2019.

View full profile

Xiuqian Mu, MD, PhD

Regulation of mRNA decay in retinal development and maintenance. Xiuqian Mu (Principal Investigator). National Eye Institute. $2,024,085. 4/1/2020-3/1/2024.
Regulatory mechanisms for retinal ganglion cell genesis. Xiuqian Mu (Principal Investigator). National Institutes of Health. $1,960,167. 9/1/2017-5/1/2022.
Generation of retinal ganglion cells by direct reprograming. Xiuqian Mu (Principal Investigator). BrightFocus Foundation. $150,000. 6/1/2016-5/1/2018.

View full profile

Sangita Patel, MD, PhD

Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Sangita Patel (Co-Investigator), Michael Duffey (Co-Investigator), Mark Parker (Principal Investigator). National Institutes of Health. $1,972,804. 2/1/2018-1/1/2023.

View full profile

Sarah Zhang, MD

Molecular Mechanisms of Severe Diabetic Retinopathy. Sarah Zhang (Principal Investigator). NIH. 2/1/2020-1/1/2024.
Targeting Neuroinflammation for RGC Protection in Glaucoma. Sarah Zhang (Principal Investigator). BrightFocus Foundation. 7/1/2019-6/1/2021.
ER stress and diabetic retinopathy (Admin Supplements). Sarah Zhang (Principal Investigator). NIH, NEI. 9/1/2018-8/1/2020.
ER stress and diabetic retinopathy. Sarah Zhang (Principal Investigator). NIH, NEI. 9/1/2010-2/1/2024.

View full profile